Epidermal growth factor receptor expression status in lung cancer correlates with its mutation

Makoto Suzuki, Hisayuki Shigematsu, Kenzo Hiroshima, Toshihiko Iizasa, Yukio Nakatani, John D. Minna, Adi F. Gazdar, Takehiko Fujisawa

Research output: Contribution to journalArticle

46 Citations (Scopus)

Abstract

The molecular mechanisms for frequent epidermal growth factor receptor (EGFR, a tyrosine kinase [TK]) and HER2 (the preferred coreceptor of EGFR) overexpression in lung cancer are poorly understood. Recent studies have shown the mutations of the TK domain in EGFR and HER2 to be present in lung cancer. The purpose of this study was to investigate the relationship between mutation status and expression of EGFR and HER2 in lung cancer. Immunostaining took place for EGFR and HER2, and mutational analyses for EGFR, HER2, and KRAS (a signaling protein) were conducted using 130 resected lung cancer specimens. Thirty-seven EGFR mutations (28%) and 8 HER2 mutations (6%), both of the TK domains, and 5 KRAS (4%) mutations were found, whereas 73 (56%) EGFR and 47 (36%) HER2 overexpressions were found. EGFR overexpression was seen more frequently in tumors with EGFR mutation (28/37, 76%) than in tumors without EGFR mutations (45/93, 48%; P = .0059). No correlation was found between HER2 mutation and HER2 expression. Multivariate regression revealed that EGFR mutation, adenocarcinoma histology, and HER2 expression were associated with EGFR expression, whereas female sex, EGFR mutation, and EGFR expression were associated with HER2 expression. In conclusion, EGFR and HER2 overexpression is frequent in lung cancer, and EGFR overexpression correlates with the EGFR TK domain mutations.

Original languageEnglish (US)
Pages (from-to)1127-1134
Number of pages8
JournalHuman Pathology
Volume36
Issue number10
DOIs
StatePublished - Oct 2005

Fingerprint

Epidermal Growth Factor Receptor
Lung Neoplasms
Mutation
Protein-Tyrosine Kinases
Neoplasms
Histology
Adenocarcinoma

Keywords

  • EGFR
  • Expression
  • HER2
  • KRAS
  • Lung cancer
  • Mutation

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Suzuki, M., Shigematsu, H., Hiroshima, K., Iizasa, T., Nakatani, Y., Minna, J. D., ... Fujisawa, T. (2005). Epidermal growth factor receptor expression status in lung cancer correlates with its mutation. Human Pathology, 36(10), 1127-1134. https://doi.org/10.1016/j.humpath.2005.08.007

Epidermal growth factor receptor expression status in lung cancer correlates with its mutation. / Suzuki, Makoto; Shigematsu, Hisayuki; Hiroshima, Kenzo; Iizasa, Toshihiko; Nakatani, Yukio; Minna, John D.; Gazdar, Adi F.; Fujisawa, Takehiko.

In: Human Pathology, Vol. 36, No. 10, 10.2005, p. 1127-1134.

Research output: Contribution to journalArticle

Suzuki, M, Shigematsu, H, Hiroshima, K, Iizasa, T, Nakatani, Y, Minna, JD, Gazdar, AF & Fujisawa, T 2005, 'Epidermal growth factor receptor expression status in lung cancer correlates with its mutation', Human Pathology, vol. 36, no. 10, pp. 1127-1134. https://doi.org/10.1016/j.humpath.2005.08.007
Suzuki, Makoto ; Shigematsu, Hisayuki ; Hiroshima, Kenzo ; Iizasa, Toshihiko ; Nakatani, Yukio ; Minna, John D. ; Gazdar, Adi F. ; Fujisawa, Takehiko. / Epidermal growth factor receptor expression status in lung cancer correlates with its mutation. In: Human Pathology. 2005 ; Vol. 36, No. 10. pp. 1127-1134.
@article{1cd379d602d24acbaef681c6f12db16a,
title = "Epidermal growth factor receptor expression status in lung cancer correlates with its mutation",
abstract = "The molecular mechanisms for frequent epidermal growth factor receptor (EGFR, a tyrosine kinase [TK]) and HER2 (the preferred coreceptor of EGFR) overexpression in lung cancer are poorly understood. Recent studies have shown the mutations of the TK domain in EGFR and HER2 to be present in lung cancer. The purpose of this study was to investigate the relationship between mutation status and expression of EGFR and HER2 in lung cancer. Immunostaining took place for EGFR and HER2, and mutational analyses for EGFR, HER2, and KRAS (a signaling protein) were conducted using 130 resected lung cancer specimens. Thirty-seven EGFR mutations (28{\%}) and 8 HER2 mutations (6{\%}), both of the TK domains, and 5 KRAS (4{\%}) mutations were found, whereas 73 (56{\%}) EGFR and 47 (36{\%}) HER2 overexpressions were found. EGFR overexpression was seen more frequently in tumors with EGFR mutation (28/37, 76{\%}) than in tumors without EGFR mutations (45/93, 48{\%}; P = .0059). No correlation was found between HER2 mutation and HER2 expression. Multivariate regression revealed that EGFR mutation, adenocarcinoma histology, and HER2 expression were associated with EGFR expression, whereas female sex, EGFR mutation, and EGFR expression were associated with HER2 expression. In conclusion, EGFR and HER2 overexpression is frequent in lung cancer, and EGFR overexpression correlates with the EGFR TK domain mutations.",
keywords = "EGFR, Expression, HER2, KRAS, Lung cancer, Mutation",
author = "Makoto Suzuki and Hisayuki Shigematsu and Kenzo Hiroshima and Toshihiko Iizasa and Yukio Nakatani and Minna, {John D.} and Gazdar, {Adi F.} and Takehiko Fujisawa",
year = "2005",
month = "10",
doi = "10.1016/j.humpath.2005.08.007",
language = "English (US)",
volume = "36",
pages = "1127--1134",
journal = "Human Pathology",
issn = "0046-8177",
publisher = "W.B. Saunders Ltd",
number = "10",

}

TY - JOUR

T1 - Epidermal growth factor receptor expression status in lung cancer correlates with its mutation

AU - Suzuki, Makoto

AU - Shigematsu, Hisayuki

AU - Hiroshima, Kenzo

AU - Iizasa, Toshihiko

AU - Nakatani, Yukio

AU - Minna, John D.

AU - Gazdar, Adi F.

AU - Fujisawa, Takehiko

PY - 2005/10

Y1 - 2005/10

N2 - The molecular mechanisms for frequent epidermal growth factor receptor (EGFR, a tyrosine kinase [TK]) and HER2 (the preferred coreceptor of EGFR) overexpression in lung cancer are poorly understood. Recent studies have shown the mutations of the TK domain in EGFR and HER2 to be present in lung cancer. The purpose of this study was to investigate the relationship between mutation status and expression of EGFR and HER2 in lung cancer. Immunostaining took place for EGFR and HER2, and mutational analyses for EGFR, HER2, and KRAS (a signaling protein) were conducted using 130 resected lung cancer specimens. Thirty-seven EGFR mutations (28%) and 8 HER2 mutations (6%), both of the TK domains, and 5 KRAS (4%) mutations were found, whereas 73 (56%) EGFR and 47 (36%) HER2 overexpressions were found. EGFR overexpression was seen more frequently in tumors with EGFR mutation (28/37, 76%) than in tumors without EGFR mutations (45/93, 48%; P = .0059). No correlation was found between HER2 mutation and HER2 expression. Multivariate regression revealed that EGFR mutation, adenocarcinoma histology, and HER2 expression were associated with EGFR expression, whereas female sex, EGFR mutation, and EGFR expression were associated with HER2 expression. In conclusion, EGFR and HER2 overexpression is frequent in lung cancer, and EGFR overexpression correlates with the EGFR TK domain mutations.

AB - The molecular mechanisms for frequent epidermal growth factor receptor (EGFR, a tyrosine kinase [TK]) and HER2 (the preferred coreceptor of EGFR) overexpression in lung cancer are poorly understood. Recent studies have shown the mutations of the TK domain in EGFR and HER2 to be present in lung cancer. The purpose of this study was to investigate the relationship between mutation status and expression of EGFR and HER2 in lung cancer. Immunostaining took place for EGFR and HER2, and mutational analyses for EGFR, HER2, and KRAS (a signaling protein) were conducted using 130 resected lung cancer specimens. Thirty-seven EGFR mutations (28%) and 8 HER2 mutations (6%), both of the TK domains, and 5 KRAS (4%) mutations were found, whereas 73 (56%) EGFR and 47 (36%) HER2 overexpressions were found. EGFR overexpression was seen more frequently in tumors with EGFR mutation (28/37, 76%) than in tumors without EGFR mutations (45/93, 48%; P = .0059). No correlation was found between HER2 mutation and HER2 expression. Multivariate regression revealed that EGFR mutation, adenocarcinoma histology, and HER2 expression were associated with EGFR expression, whereas female sex, EGFR mutation, and EGFR expression were associated with HER2 expression. In conclusion, EGFR and HER2 overexpression is frequent in lung cancer, and EGFR overexpression correlates with the EGFR TK domain mutations.

KW - EGFR

KW - Expression

KW - HER2

KW - KRAS

KW - Lung cancer

KW - Mutation

UR - http://www.scopus.com/inward/record.url?scp=26644465742&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=26644465742&partnerID=8YFLogxK

U2 - 10.1016/j.humpath.2005.08.007

DO - 10.1016/j.humpath.2005.08.007

M3 - Article

C2 - 16226114

AN - SCOPUS:26644465742

VL - 36

SP - 1127

EP - 1134

JO - Human Pathology

JF - Human Pathology

SN - 0046-8177

IS - 10

ER -